Showing 7301-7310 of 8826 results for "".
- FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Patients 9 Years and Olderhttps://practicaldermatology.com/news/fda-approves-arcutis-zoryve-roflumilast-topical-foam-03-for-the-treatment-of-seborrheic-dermatitis-in-patients-9-years-and-older/2462186/Arcutis Biotherapeutics, Inc. announced the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for ZORYVE (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in those 9 years of age and older. ZORYVE foam provides rapid disease clearance and
- Study: Implementing a Treat-to-Target Approach Can Benefit PsA Patientshttps://practicaldermatology.com/news/implementation-of-the-treat-to-target-approach-in-psoriatic-arthritis-and-its-outcomes-in-routine-clinical-practice/2462181/A new study published in Cureus showed measuring disease activity with validated tools and treating to target (T2T) in patients with psoriatic arthritis (PsA) is crucial to improving quality of life and better disease control. The first-ever retrospective review from
- Intradermal AIV001 Found Safe in Early BCC Studyhttps://practicaldermatology.com/news/intradermal-aiv001-found-safe-in-early-bcc-study/2462178/AiViva Biopharma Inc. completed its first trial administering AIV001 (axitinib) to patients diagnosed with basal cell carcinoma (BCC) tumors. AIV001 is intradermally administered and designed for local, prolonged treatment effect for dermatological conditions. The phase
- Kymera Update: First Patient Dosed in Phase 2 AD Clinical Trial of KT-474, a First-in-Class Investigational IRAK4 Degraderhttps://practicaldermatology.com/news/kymera-update-first-patient-dosed-in-phase-2-ad-clinical-trial-of-kt-474-a-first-in-class-investigational-irak4-degrader/2462177/The first patient has been dosed in the Phase 2 clinical trial (ADVANTA) evaluating KT-474 in AD, generating a $15 million milestone payment under its collaboration with Sanofi. KT-474 is an oral IRAK4 degrader, in development for the treatment of IL-1R/TLR-driven complex inflamma
- AI in Action: Almirall, Barcelona Supercomputing Center, and Nostrum Biodiscovery Seek New Dermatologic Therapies via AIhttps://practicaldermatology.com/news/ai-in-action-almirall-barcelona-supercomputing-center-bsc-and-nostrum-biodiscovery-seek-new-dermatologic-therapies-via-ai/2462171/Almirall S.A. (BME: ALM), Barcelona Supercomputing Center-Centro Nacional de Supercomputación (BSC-CNS) and Nostrum Biodiscovery are joining forces to explore artificial intelligence (AI) and machine learning (ML) generative approaches to design new protein-protein modulators for dermatolo
- Shmuel Gov Named COO of Strata Skin Scienceshttps://practicaldermatology.com/news/shmuel-gov-named-coo-at-strata-skin-sciences/2462169/Shmuel Gov is the new Chief Operating Officer (COO) of STRATA Skin Sciences. The Company has also hired Dr. Amandeep Kaur as Vice President of Marketing and Business Growth. Mr. Gov brings more than 30 years of industry experience in medical device business, operations, and R&
- DermWire’s AD Pipeline Watch: TDM 180935 Performs Well in Phase 1 Studyhttps://practicaldermatology.com/news/dermwires-ad-pipeline-watch-tdm-180935-performs-well-in-phase-1-study/2462168/Technoderma Medicines, Inc. has completed a Phase 1 clinical trial of TDM-180935 topical ointment for Atopic Dermatitis (AD). TDM 180935 is a small molecule drug candidate that functions as a potent JAK1/Tyk2 small molecule inhibitor. Preclinical assessment of TDM-180935 has demon
- NPs and PAs Value Prognostic Information From DecisionDx-Melanomahttps://practicaldermatology.com/news/nps-and-pas-value-prognostic-information-from-decisiondx-melanoma/2462163/More than 90% of nurse practitioners and physician assistants(NPs/PAs), agree that prognostic information about a patient’s melanoma is valuable and improves patient care, , according to new study looking at use of DecisionDx-Melanoma in the Jo
- Is Separating the Good Skin T Cells from the Bad Ones a Key to Treating Psoriasis and Vitiligo?https://practicaldermatology.com/news/is-separating-the-good-skin-t-cells-from-the-bad-ones-a-key-to-treating-psoriasis-and-vitiligo/2462162/New research highlights ways to remove immune cells that cause autoimmune skin diseases such as psoriasis and vitiligo without affecting protective cells that fight infection and cancer. Tissue-resident T cells or TRM cells fight infections and cancerous cells in the skin, but
- FDA Accepts Arcutis’ sNDA for Roflumilast Cream 0.15% for Treatment of AD in Adults and Children Down to Age 6https://practicaldermatology.com/news/fda-accepts-arcutis-snda-for-roflumilast-cream-015-for-treatment-of-ad-in-adults-and-children-down-to-age-6/2462159/The U.S. Food and Drug Administration (FDA) has accepted Arcutis’ supplemental new drug application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in adults and children down to age 6. Roflumilast cream is a once-daily, steroid